Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials

This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease. In this trial, high throughput analysis will be carried out using next generation sequencing, and immunological profiling. Patients included in the BIP study and for whom a targetable genomic alteration had been identified might be subsequently included in an early phase trials running at Institut Bergonie or another French hospital.

NCT Number	NCT02534649
Lead Sponsor	Institut Bergonié
Conditions	Solid Tumor, Hematological Malignancy
Enrollment	10,000 participants
Start Date	2015-12
Primary Completion	2028-03 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2025-10-02